Health
FDA Approves New Dosing Option for CRYSVITA® (burosumab-twza) in Adults With XLH
Expanded dosing options support individualized treatment for adults with XLH PRINCETON, N.J., May 14, 2026 (GLOBE NEWSWIRE) -- Kyowa Kirin, Inc., a wholly owned subsidiary of Kyowa Kirin Co. Ltd., today announced the U.S. Food and Drug Administration (FDA) has approved a dosing update to the CRYSVITA® (burosumab-twza) Prescribing Information for adults living with X-linked hypophosphatemia (XLH), a rare, progressive, genetic disease that impacts the bones and muscles in both children and adults.
About this update from Kyowa Kirin Co., Ltd.
[{"type":"image","alt":"Kyowa Kirin","displaySize":"","headline":null,"caption":"Kyowa Kirin","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":58,"url":"https://media.zenfs.com/en/globenewswire.com/b9c3225d04b222adf60766e494f98867"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/fIKdZA6jEi2DlyHW8g1mHQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTgx/https://media.zenfs.com/en/globenewswire.com/b9c3225d04b222adf60766e494f98867","width":300,"height":58},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/fIKdZA6jEi2DlyHW8g1mHQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTgx/https://media.zenfs.com/en/globenewswire.com/b9c3225d04b222adf60766e494f98867","width":300,"height":58}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Expanded dosing options support individualized treatment for adults with XLH","length":76,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":76,"olType":false},{"type":"text","content":"PRINCETON, N.J., May 14, 2026 (GLOBE NEWSWIRE) -- Kyowa Kirin, Inc., a wholly owned subsidiary of Kyowa Kirin Co. Ltd., today announced the U.S. Food and Drug Administration (FDA) has approved a dosing update to the CRYSVITA® (burosumab-twza) Prescribing Information for adults living with X-linked hypophosphatemia (XLH), a rare, progressive, genetic disease that impacts the bones and muscles in both children and adults. Healthcare providers now have the option to increase the dose and frequency of CRYSVITA for patients whose serum phosphorus is below the normal range after the initial treatment period. These patients may be transitioned to a dosage of 0.5 mg/kg, not to exceed 90 mg, once every 2 weeks. If further dosage increase is needed after 4 weeks of treatment with 0.5 mg/kg every 2 weeks, the dosage can be increased to 1 mg/kg, not to exceed 90 mg, administered every 2 weeks.","length":894,"tagName":"p"},{"type":"text","content":"“Kyowa Kirin is committed to delivering solutions that make a meaningful difference for people living with XLH. As the only FDA-approved treatment for XLH, CRYSVITA plays a critical role in care, and it’s essential that clinicians have the flexibility to support optimal patient outcomes,” said Richard Wilson, Senior Vice President, Rare Disease Franchise Head. “While most adults with XLH maintain normal serum phosphorus levels with CRYSVITA administered every four we...